![]() POCT makes it possible to diagnose and treat patients quickly, which is crucial in emergency situations. The growth of artificial intelligence (AI) and machine learning (ML) technologies in the clinical laboratory services market is also due to the increasing adoption of digital pathology platforms.ĭue to the large number of clinical chemistry tests performed in the US, the rapid acceptance of new technologies, and the development of point-of-care testing techniques in the nation, the clinical chemistry testing sector had the largest market share in 2022, with revenues of US$ 31.1 Bn. Additionally, it makes it possible to assess the effectiveness of brand-new medications and create companion diagnostics that may use to find individuals who will respond best to a certain course of treatment. With the help of digital pathology, diagnoses may provide more accurately and quickly, which can result in earlier diagnoses and improved treatment outcomes. Digital pathology systems are particularly crucial for the detection and management of cancer. Large biopharmaceuticals and top clinical research organizations (CROs) are increasingly using digital pathology to speed up the discovery, pre-clinical, and clinical trial phases of drug development. Additionally, indications for treating familial hypercholesterolemia and generalized myasthenia are recent examples of personalized medicine approvals. Examples of personalized medicine include tumor marker testing for cancer diagnosis and tailored medicines recommended for the treatment of breast cancer. Research is looking into other fields where personalized medicine may use to treat and diagnose other diseases. Oncology is one of the fields in customized medicine that is expanding rapidly. Due to this, there is now a higher need for genetic testing services, which is likely to propel market expansion in the upcoming years. Healthcare professionals can now offer individualized treatment programs that take a person’s genetic composition into account thanks to developments in genomics and genetic testing. This emphasizes the demand for more clinical services in the US clinical laboratory services market to address chronic illnesses in the geriatric population. Approximately 80% of persons over 65 have at least one chronic disease, and 68% have two or more, according to the Centers for Disease Control and Prevention (CDC). The US has an aging population, and by 2050, there will be twice as many people over 65. Major risk factors for chronic diseases include poor diet, inactivity, and cigarette use. Chronic diseases are becoming more prevalent in the clinical laboratory services market, which is also being fueled by unhealthy lifestyle choices and environmental factors. These and other chronic illnesses are the main contributors to healthcare costs and the major causes of death and disability in the United States. The Centers for Disease Control and Prevention estimate that six out of ten Americans have at least one chronic illness, such as diabetes, cancer, heart disease, or a stroke. ![]()
0 Comments
Leave a Reply. |